BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7386999)

  • 1. Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.
    Chatterjee K; Ports TA; Brundage BH; Massie B; Holly AN; Parmley WW
    Ann Intern Med; 1980 May; 92(5):600-4. PubMed ID: 7386999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.
    Elkayam U; Weber L; McKay CR; Rahimtoola SH
    Am J Cardiol; 1984 Jul; 54(1):126-31. PubMed ID: 6741802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.
    Franciosa JA; Pierpont G; Cohn JN
    Ann Intern Med; 1977 Apr; 86(4):388-93. PubMed ID: 848799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
    Nelson GI; Silke B; Forsyth DR; Verma SP; Hussain M; Taylor SH
    Am J Cardiol; 1983 Nov; 52(8):1036-40. PubMed ID: 6637819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydralazine in chronic CHF.
    Chatterjee K; Rouleau JL; Massie BM
    Acta Med Scand Suppl; 1981; 652():99-113. PubMed ID: 6949469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral hydralazine therapy for chronic refractory heart failure.
    Chatterjee K; Parmley WW; Massie B; Greenberg B; Werner J; Klausner S; Norman A
    Circulation; 1976 Dec; 54(6):879-83. PubMed ID: 825327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.
    Rubin SA; Chatterjee K; Ports TA; Gelberg HJ; Brundage BH; Parmley WW
    Am J Cardiol; 1979 Nov; 44(6):1183-9. PubMed ID: 495513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.
    Massie BM; Packer M; Hanlon JT; Combs DT
    J Am Coll Cardiol; 1983 Aug; 2(2):338-44. PubMed ID: 6345633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure.
    LeJemtel TH; Elkayam U; Ribner HS; Hellman C; Strom J; Frishman W; Strobeck J; Sonnenblick EH
    Eur Heart J; 1980 Jun; 1(3):157-63. PubMed ID: 7026250
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydralazine in heart failure.
    Chatterjee K
    Herz; 1983 Aug; 8(4):187-98. PubMed ID: 6413340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure.
    Quyyumi AA; Wagstaff D; Evans TR
    Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.
    Pierpont GL; Cohn JN; Franciosa JA
    Chest; 1978 Jan; 73(1):8-13. PubMed ID: 620563
    [No Abstract]   [Full Text] [Related]  

  • 14. Afterload reduction with hydralazine following valve replacement.
    Marco JD; Standeven JW; Barner HB
    J Thorac Cardiovasc Surg; 1980 Jul; 80(1):50-3. PubMed ID: 7382535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
    Chatterjee K; Ports TA; Arnold S; Brundage B; Parmley W
    Br Heart J; 1979 Dec; 42(6):657-63. PubMed ID: 534582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response.
    Goldberg MJ; Franklin BA; Rubenfire M; Kerin NZ; Willens HJ; Ruskin R
    J Am Coll Cardiol; 1983 Nov; 2(5):887-93. PubMed ID: 6313788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
    Rubin LJ; Handel F; Peter RH
    Circulation; 1982 Jun; 65(7):1369-73. PubMed ID: 7074795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained effect of hydralazine in long term treatment of CHF.
    Conradson TB; Rydén L
    Acta Med Scand Suppl; 1981; 652():173-6. PubMed ID: 6800217
    [No Abstract]   [Full Text] [Related]  

  • 19. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
    Gogia H; Mehra A; Parikh S; Raman M; Ajit-Uppal J; Johnson JV; Elkayam U
    J Am Coll Cardiol; 1995 Dec; 26(7):1575-80. PubMed ID: 7594088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.